Veeva Systems delivered a solid QQ2 2026 quarter, underscoring the company’s leadership in cloud-based life sciences software. Revenue reached $789.1 million, up 16.7% year over year and 3.96% quarter over quarter, while gross margins remained robust at approximately 75.3%. Operating income of $226.5 million produced an operating margin of 28.7%, and net income of $200.3 million yielded a net margin of 25.4%. EBITDA stood at roughly $255.5 million, reflecting durable profitability in a high-value software portfolio. The balance sheet remains exceptionally strong, with ~$6.4 billion in cash and short-term investments and a net cash position of about $1.845 billion. Deferred revenue sits at ~$1.108 billion, providing revenue visibility and multi-year revenue recognition tailwinds that support sustainable cash flow.